ImmusanT
Cambridge
About ImmusanT
ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $72.8M
- Last round: Series Unknown (Sep 2018)
- Website: immusant.com
- Phone: 617-299-8399
Industries & Categories
Biotechnology, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immusant-23078 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.